Spots Global Cancer Trial Database for recombinant human endostatin
Every month we try and update this database with for recombinant human endostatin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Endostatin in Treating Patients With Advanced Solid Tumors | NCT00004229 | Unspecified Adu... | recombinant hum... | 18 Years - | National Cancer Institute (NCI) | |
| Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer | NCT01310478 | Colorectal Neop... | recombinant hum... | 17 Years - 70 Years | Fudan University | |
| First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial | NCT05574998 | Non-Small-Cell ... | Recombinant hum... | 18 Years - 75 Years | Qianfoshan Hospital | |
| FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer | NCT00813137 | Colorectal Neop... | Folfox4 plus re... | 18 Years - 75 Years | Simcere Pharmaceutical Co., Ltd | |
| Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer | NCT01310478 | Colorectal Neop... | recombinant hum... | 17 Years - 70 Years | Fudan University | |
| Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC | NCT02005120 | Non Small Cell ... | Bevacizumab recombinant hum... | 18 Years - 75 Years | Zhejiang University | |
| Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy | NCT06279754 | Locally Advance... | Recombinant Hum... | 18 Years - 70 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer | NCT03588494 | Quality of Life | concurrent chem... Endostar for on... Endostar for tw... | 18 Years - 70 Years | Affiliated Hospital of North Sichuan Medical College | |
| Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC | NCT03008109 | Advanced Cancer Lung Cancer, No... | EGFR-TK Inhibit... | 18 Years - | Air Force General Hospital of the PLA | |
| Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance. | NCT02350361 | Lung Cancer | Recombinant hum... Placebo | 18 Years - 75 Years | Peking University Third Hospital | |
| Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma | NCT01612286 | Nasopharyngeal ... | endostatin | 18 Years - 65 Years | Zhejiang Cancer Hospital | |
| First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial | NCT05574998 | Non-Small-Cell ... | Recombinant hum... | 18 Years - 75 Years | Qianfoshan Hospital | |
| Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC) | NCT01124253 | Non-small Cell ... | recombinant hum... | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| Endostatin in Treating Patients With Advanced Solid Tumors | NCT00004229 | Unspecified Adu... | recombinant hum... | 18 Years - | National Cancer Institute (NCI) | |
| Modified CV Regimen in Optic Pathway Glioma | NCT05278715 | Optic Glioma Pediatric Brain... | Carboplatin Vincristine Recombinant hum... | 3 Months - 21 Years | Beijing Sanbo Brain Hospital | |
| Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma | NCT03095079 | Melanoma | recombinant hum... | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC) | NCT03208335 | Hepatocellular ... | recombinant hum... | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors | NCT03989830 | Head and Neck N... | second-line che... Recombinant hum... | 18 Years - 75 Years | Peking University | |
| Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC) | NCT03208335 | Hepatocellular ... | recombinant hum... | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma | NCT01612286 | Nasopharyngeal ... | endostatin | 18 Years - 65 Years | Zhejiang Cancer Hospital | |
| Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors | NCT03989830 | Head and Neck N... | second-line che... Recombinant hum... | 18 Years - 75 Years | Peking University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
